MIRA Pharmaceuticals Joins BIO Convention for Strategic Opportunities

MIRA Pharmaceuticals, Inc. ( (MIRA) ) has provided an update.

On May 28, 2025, MIRA Pharmaceuticals announced its participation in the BIO International Convention 2025 in Boston, aiming to explore licensing, strategic collaborations, and M&A opportunities. The company is advancing its clinical programs, with its lead candidate, Ketamir-2, progressing through Phase 1 trials and preparing for Phase IIa trials by the end of 2025. Additionally, MIRA is finalizing regulatory filings for its acquisition of SKNY Pharmaceuticals, which focuses on treatments for smoking cessation and obesity.

The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapeutic solutions. The company is primarily engaged in advancing clinical and preclinical programs, with a market focus on non-opioid alternatives for chronic pain management and treatments for conditions like PTSD, smoking cessation, and obesity.

Average Trading Volume: 1,341,657

Technical Sentiment Signal: Hold

For detailed information about MIRA stock, go to TipRanks’ Stock Analysis page.